Why is uncompetitive inhibition so rare? A possible explanation, with implications for the design of drugs and pesticides.
about
The purification and properties of myo-inositol monophosphatase from bovine brainAn unusual case of 'uncompetitive activation' by ascorbic acid: purification and kinetic properties of a myrosinase from Raphanus sativus seedlingsMechanism of inositol monophosphatase, the putative target of lithium therapyMathematical and computational modeling in biology at multiple scalesMechanism of inhibition of growth of 3T3-L1 fibroblasts and their differentiation to adipocytes by dehydroepiandrosterone and related steroids: role of glucose-6-phosphate dehydrogenase.Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.Glyphosate resistance: state of knowledgeEnolase: a key player in the metabolism and a probable virulence factor of trypanosomatid parasites-perspectives for its use as a therapeutic target.Eosin B as a novel antimalarial agent for drug-resistant Plasmodium falciparum.Discovery of a novel inhibitor of NAD(P)(+)-dependent malic enzyme (ME2) by high-throughput screening.Lithium-induced disruption of cell signalling in brain: evidence implicating the phosphoinositide cycle.Toward a crystal-clear view of lithium's site of action.Hydroxybenzaldoximes Are D-GAP-Competitive Inhibitors of E. coli 1-Deoxy-D-Xylulose-5-Phosphate SynthaseOn the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death.Transient kinetics of aminoglycoside phosphotransferase(3')-IIIa reveals a potential drug target in the antibiotic resistance mechanism.1,4-naphthoquinones and other NADPH-dependent glutathione reductase-catalyzed redox cyclers as antimalarial agentsInhibition of Non-flux-Controlling Enzymes Deters Cancer Glycolysis by Accumulation of Regulatory Metabolites of Controlling StepsGlucose-6-phosphate dehydrogenase of trypanosomatids: characterization, target validation, and drug discoveryA small-molecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase.Beryllium competitively inhibits brain myo-inositol monophosphatase, but unlike lithium does not enhance agonist-induced inositol phosphate accumulation.Characteristics necessary for an interconvertible enzyme cascade to generate a highly sensitive response to an effector.Stimulation of histone deacetylase activity by metabolites of intermediary metabolismA kinetic investigation of the acyl-CoA oxidase reaction with the use of a novel spectrophotometric assay. Inhibition by acetyl-CoA, CoA and FMN.Dephosphorylation of 1D-myo-inositol 1,4-bisphosphate in rat liver.Identification of Bidentate Salicylic Acid Inhibitors of PTP1B.Classification of difference between inhibition constants of an inhibitor to facilitate identifying the inhibition type.Kinetic characterization of the inhibition of protein tyrosine phosphatase-1B by Vanadyl (VO2+) chelates.Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.A new 4-arylflavan from the pericarps of Horsfieldia motleyi displaying dual inhibition against α-glucosidase and free radicals.Autoinflammatory Reaction in Dogs Treated for Cancer via G6PD Inhibition.Detection of a novel, primate-specific 'kill switch' tumor suppression mechanism that may fundamentally control cancer risk in humans: an unexpected twist in the basic biology of TP53
P2860
Q24529508-DB8ACAC9-E231-4B47-B639-35EA52DAD619Q24531600-7085E041-99F1-49CD-A8AF-DEAAE8B9B276Q24562775-0940A6F5-77D2-4BED-B0CC-99AA1FE879ACQ28082151-30F0880C-8485-482B-97D5-4BBF73FB58A8Q33859257-F827F3E9-7FCF-4393-92E1-DF31D38BC397Q34646772-6D9B01E9-0887-4366-9D48-280F674ACFF4Q34657222-58F6CD3A-E2E0-4646-8D0C-5952C52530F2Q34659035-82426EB8-E773-450D-9F93-81FA5FC8E97BQ34975047-C0660BE4-3311-476B-AFC5-D3D7477D6CE2Q35023226-F3A6174D-7435-4685-9967-C819265B1AC1Q35135050-9A4E14C3-1E6F-4A02-AFAD-A9CC7E1C3D8BQ35237779-D805FDD9-4CCA-4824-9CED-E93EF871E331Q35529747-D37FAC2A-0EB4-41C9-8992-5DBB3DCF7FADQ35691316-6CC82F12-D772-4056-AEB2-5C35D3F4EBE0Q35765830-D3D1F72E-3815-4E65-B2A3-4029CC700DDAQ36434917-D0803BB8-9752-4ADD-A894-FE9B3E54685DQ36914067-14815ABE-313D-4844-AA95-E0C55CDEBD85Q37277390-50B85578-3EB3-450B-9EEB-801BC9B6B2B9Q38746177-92FFF871-E663-42FF-AA1A-CB71F8E99619Q40149380-4FF3422B-75DA-4B54-A625-1AE368F548F6Q41559905-6D48A1CB-4EA4-4E90-981B-8722425F1521Q42064347-5311BCFE-F67E-4EDF-A7ED-EB9DBC1B9EA6Q42325395-EEA27BA4-087F-4823-BCB1-A6EABEFD7263Q42803693-3ABCE4A0-63CE-4883-B055-CA25BB9567B6Q42817591-76CB42D4-F24F-448B-B85D-7AD1E6EE1BCDQ43242949-C218DB0A-05B1-46B4-8ADE-B21A814E880CQ46266969-BF626497-94EE-4471-BDE1-7788217B266AQ47602319-7065C18D-EC66-49DE-A728-E10AB1356447Q48015244-FD2FEAF8-56AA-467B-BDFB-A637FCD35324Q50049632-6887AC5E-FC06-4FD3-8BCD-C45DE1021D34Q55408020-22AF4783-E95A-48AF-BB9B-2DB9DE85934DQ57211763-5729C3FF-BFB7-499E-AD0F-C370D4606D5D
P2860
Why is uncompetitive inhibition so rare? A possible explanation, with implications for the design of drugs and pesticides.
description
1986 nî lūn-bûn
@nan
1986 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Why is uncompetitive inhibitio ...... esign of drugs and pesticides.
@ast
Why is uncompetitive inhibitio ...... esign of drugs and pesticides.
@en
Why is uncompetitive inhibitio ...... esign of drugs and pesticides.
@nl
type
label
Why is uncompetitive inhibitio ...... esign of drugs and pesticides.
@ast
Why is uncompetitive inhibitio ...... esign of drugs and pesticides.
@en
Why is uncompetitive inhibitio ...... esign of drugs and pesticides.
@nl
prefLabel
Why is uncompetitive inhibitio ...... esign of drugs and pesticides.
@ast
Why is uncompetitive inhibitio ...... esign of drugs and pesticides.
@en
Why is uncompetitive inhibitio ...... esign of drugs and pesticides.
@nl
P2860
P1433
P1476
Why is uncompetitive inhibitio ...... esign of drugs and pesticides.
@en
P2093
Cornish-Bowden A
P2860
P356
10.1016/0014-5793(86)81424-7
P407
P577
1986-07-01T00:00:00Z